|
Samaritan
Pharma Retains The Investor Relations Group of New York
Tuesday December 4, 10:51 am
ET
Return
to Homepage | See All News
IRG
to Strive to Increase Investor, Media, and Industry
Awareness
Samaritan
Pharmaceuticals, Inc. (OTC BB:SPHC.OB), a biopharmaceutical
company focused on developing innovative therapeutics
in the areas of CNS, cancer, cardiovascular, and infectious
diseases, has retained The Investor Relations Group,
Inc. (IRG), based in New York City, to serve as its
investor relations and corporate communications firm.
Samaritan's
collaborative researchers have made important patented
discoveries in the fields of central nervous system
diseases, such as Alzheimer's disease, cancer, and cardiovascular
disease; and infectious diseases, such as AIDS and Hepatitis
C. These discoveries have positioned the company with
a rich pipeline of new drugs with novel mechanisms of
actions to develop. The company's strategy is to identify
promising drugs, bring them through the FDA investigational
new drug (IND) application process, initiate proof of
concept Phase I/II clinical trials and commercialize
innovative products by licensing to major pharmaceutical
partners.
Dr. Janet Greeson, CEO of Samaritan Pharmaceuticals
commented, "We have made substantial accomplishments
in developing our clinical development pipeline, as
well as establishing numerous collaborative relationships
with specialty pharmaceutical companies to market and
sell their approved prescription drugs in Greece and
Eastern Europe. As we move forward with our growth strategy,
we feel the timing is right for The Investor Relations
Group to play an integral role in communicating Samaritan's
message to the investment community and the media-at-large.''
|
|
"...As
we move forward with our growth strategy, we feel
the timing is right for The Investor Relations
Group to play an integral role in communicating
Samaritan's message to the investment community
and the media-at-large.''
Dr.
Janet Greeson
CEO Samaritan Pharmaceuticals |
|
IRG will strive
to increase investor and industry awareness of Samaritan Pharmaceuticals
within the U.S. and world markets by introducing the company
and its management to pre-qualified fund managers, analysts,
and the media.
About
The Investor Relations Group, Inc.
The Investor Relations
Group, Inc. (IRG) offers a full-service corporate communications
program designed to suit the many unique needs of Alternative
Public Offering (APO) companies. The program utilizes a proprietary,
targeted approach to reach institutional investors, analysts,
and the media-at-large. For further information, please visit
the company's website at http://www.investorrelationsgroup.com.
Samaritan
Pharmaceuticals: "Transforming Today's Science Into Tomorrow's
Cures...''
Samaritan
Pharmaceuticals is an entrepreneurial biopharmaceutical company
that concentrates its efforts toward commercializing new innovative
therapeutic products. Samaritan has partnered its Phase II
infectious disease drug SP-01A, an oral HIV viral-entry inhibitor,
to Pharmaplaz, Ireland. Additionally, its Alzheimer's drug
Caprospinol, with the potential to restore memory loss in
Alzheimer's disease patients, has been issued an IND by the
FDA. Samaritan has several drugs in nonclinical studies preparing
for IND development; it is evaluating the use of SP-1000 for
hypercholesterolemia patients and the use of SP-30 as an "oral
treatment'' for Hepatitis-C. In addition, Samaritan has acquired
the marketing and sales rights to sell eleven revenue-generating
products in various Eastern European countries.
Disclaimer
The company disclaims
any information created by an outside party and endorses only
information communicated by its press releases, filings, and
Website. This news release contains forward-looking statements
that reflect management's current beliefs about the potential
for its drug candidates, science, and technology. However,
as with any biopharmaceutical under development, there are
significant risks and uncertainties in the process of development
and regulatory review. There are no guarantees that products
will prove to be commercially successful. For additional information
about the factors that affect the company's business, please
read the company's latest Form 10-Q filed November 19, 2007.
The company undertakes no duty to update forward-looking statements.
Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210
Samaritan
Pharmaceuticals, Inc.
Kristi Eads
702-735-7001
|
